Go Pro
→ This little-known gold fund distributes cash every Friday (From Investors Alley) (Ad)tc pixel Free GENF Stock Alerts

Genflow Biosciences (GENF) Competitors

Genflow Biosciences logo
GBX 2.10 +0.05 (+2.44%)
As of 11:59 AM Eastern
Compare

GENF vs. HVO, HEMO, COIL, C4XD, and DDDD

Should you buy Genflow Biosciences stock or one of its competitors? Genflow Biosciences's main competitors and comparable companies include hVIVO (HVO), Hemogenyx Pharmaceuticals (HEMO), Roquefort Therapeutics (COIL), C4X Discovery (C4XD), and 4D pharma (DDDD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to hVIVO?

Genflow Biosciences (LON:GENF) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Genflow Biosciences has a beta of 2.268, meaning that its share price is 127% more volatile than the broader market. Comparatively, hVIVO has a beta of 1.706, meaning that its share price is 71% more volatile than the broader market.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 12.7% of hVIVO shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by insiders. Comparatively, 4.9% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

hVIVO has higher revenue and earnings than Genflow Biosciences. hVIVO is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
hVIVO£46.77M1.01£17.84M-£0.87N/A

In the previous week, hVIVO had 4 more articles in the media than Genflow Biosciences. MarketBeat recorded 4 mentions for hVIVO and 0 mentions for Genflow Biosciences. hVIVO's average media sentiment score of 0.18 beat Genflow Biosciences' score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company Overall Sentiment
Genflow Biosciences Neutral
hVIVO Neutral

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 118.34%. Given hVIVO's stronger consensus rating and higher probable upside, analysts clearly believe hVIVO is more favorable than Genflow Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genflow Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

hVIVO has a net margin of -12.48% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
hVIVO -12.48%-14.65%11.97%

Summary

hVIVO beats Genflow Biosciences on 10 of the 15 factors compared between the two stocks.

How does Genflow Biosciences compare to Hemogenyx Pharmaceuticals?

Genflow Biosciences (LON:GENF) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 25.8% of Genflow Biosciences shares are owned by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

Genflow Biosciences has a beta of 2.268, suggesting that its stock price is 127% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.501, suggesting that its stock price is 50% more volatile than the broader market.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Hemogenyx Pharmaceuticals beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to Roquefort Therapeutics?

Genflow Biosciences (LON:GENF) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 1.9% of Roquefort Therapeutics shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by company insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Roquefort Therapeutics Neutral

Genflow Biosciences has a beta of 2.268, meaning that its share price is 127% more volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market.

Genflow Biosciences has a net margin of -170.64% compared to Roquefort Therapeutics' net margin of -57,057.07%. Genflow Biosciences' return on equity of 332.06% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Summary

Roquefort Therapeutics beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

Genflow Biosciences (LON:GENF) and C4X Discovery (LON:C4XD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 52.1% of C4X Discovery shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by insiders. Comparatively, 27.1% of C4X Discovery shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

C4X Discovery has a net margin of 42.81% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat C4X Discovery's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
C4X Discovery 42.81%55.38%28.04%

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
C4X Discovery£24.68M0.00£10.57M£0.04N/A

Genflow Biosciences has a beta of 2.268, indicating that its share price is 127% more volatile than the broader market. Comparatively, C4X Discovery has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled C4X Discovery'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
C4X Discovery Neutral

Summary

C4X Discovery beats Genflow Biosciences on 8 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to 4D pharma?

Genflow Biosciences (LON:GENF) and 4D pharma (LON:DDDD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 26.8% of 4D pharma shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by insiders. Comparatively, 12.2% of 4D pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Genflow Biosciences has a beta of 2.268, meaning that its stock price is 127% more volatile than the broader market. Comparatively, 4D pharma has a beta of 2.63, meaning that its stock price is 163% more volatile than the broader market.

4D pharma has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat 4D pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
4D pharma N/A -89.48%-42.64%

Genflow Biosciences has higher earnings, but lower revenue than 4D pharma. Genflow Biosciences is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
4D pharma£718K0.00-£31.94M-£15.40N/A

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled 4D pharma'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
4D pharma Neutral

Summary

4D pharma beats Genflow Biosciences on 6 of the 10 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GENF vs. The Competition

Export
MetricGenflow BiosciencesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£11.90M£3.99B£7.20B£2.89B
Dividend YieldN/A3.61%2.53%6.17%
P/E Ratio-6.3312.25272.63364.82
Price / SalesN/A1,326.16616.7383,676.90
Price / Cash3.00105.2976.9827.89
Price / Book8.4616.1912.856.75
Net Income-£1.76M-£22.72M£3.47B£5.89B
7 Day Performance1.50%-1.18%-0.22%-0.78%
1 Month Performance25.52%12.75%8.04%2.38%
1 Year Performance134.64%53.86%25.08%22.66%

Genflow Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 2.10
+2.4%		N/A+133.3%£11.90MN/AN/A5
HVO
hVIVO
1.6578 of 5 stars		GBX 6.43
-1.8%		GBX 15
+133.5%		-32.2%£45.02M£46.77MN/AN/A
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 588
+1.4%		N/A-36.4%£39.98MN/AN/A14
COIL
Roquefort Therapeutics
N/AGBX 9.33
-1.8%		N/A-41.7%£39.82MN/AN/A9
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
This little-known gold fund distributes cash every Friday
Gold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...
Investors Alley | Sponsoredtc pixel
Gold Explorer Sits Between Barrick’s Nevada Giants
Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...
Wall Street Logic | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"
The federal government is throwing its full support behind a new class of AI technology, in what's being calle...
Stansberry Research | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Jon Najarian's #1 Energy Trade for 2026
Elon Musk just built the largest private power network in American history. Hall of Fame Trader Jon Najarian s...
Banyan Hill Publishing | Sponsoredtc pixel